Book a Meeting

Non-Fucosylated Anti-Human CCR4 (KM2760) Therapeutic Antibody (CAT#: BioBet-1806ZP) Datasheet

Target
CCR4
Isotype
IgG
Description
Non-Fucosylated Anti-Human CCR4 (KM2760) is a glycosylation-modified therapeutic biobetter antibody.
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced CCR4 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CCR4
Full Name
C-C Motif Chemokine Receptor 4
Background
CCR4 (CC Motif Chemokine Receptor 4) is a Protein Coding gene.
Diseases associated with CCR4 include Cutaneous T Cell Lymphoma and Mycosis Fungoides.
Among its related pathways are Akt Signaling and Peptide ligandbinding receptors.
Gene Ontology (GO) annotations related to this gene include Gprotein coupled receptor activity and CC chemokine receptor activity.
An important paralog of this gene is CCR5.
Alternative Names
C-C Motif Chemokine Receptor 4, Chemokine (C-C Motif) Receptor 4, C-C CKR-4, CC-CKR-4, CMKBR4, CCR-4, K5-5, C-C Chemokine Receptor Type 4,
Gene ID
1233
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
KM2760
Host
Humanized
Species Reactivity
Human
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.

Related Products

Anti-CCR4 Antibody, FcγRIIB Binding Enhanced (CAT#: AES-0622-ZP505)
Anti-CCR4 Antibody, Recycling (CAT#: AES-0622-ZP177)
Anti-CCR4 Antibody, Half-Life Extended (CAT#: AES-0622-ZP1161)
Non-Fucosylated Anti-Human CCR4 (KW-0761/AMG761) Therapeutic Antibody (CAT#: BioBet-947ZP)
Non-Fucosylated Anti-Human CCR4 (AT008) Therapeutic Antibody (CAT#: BioBet-634ZP)
Anti-CCR4 Antibody, Highly Galactosylated (CAT#: BioBet-GA-051ZP)
Non-Fucosylated Anti-Human CCR4 (KM2760-1) Therapeutic Antibody (CAT#: BioBet-1681ZP)
Non-Fucosylated Anti-Human CCR4 (Mogamulizumab/) Therapeutic Antibody (CAT#: BioBet-1815ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.